Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Supreme Court Rejects Damage Claims in Iressa Suits; Govt, AZ Win 8-Year Battle
April 15, 2013
-
BUSINESS 11 Drug Makers to Increase, 11 to Decrease Hiring Next Year; Mid-Sized Companies Most Optimistic on Hiring
April 15, 2013
-
REGULATORY Generic Roadmap: CSIMC Bill Payer Rep Says New 60% Target Could “Decelerate” Shift
April 12, 2013
-
BUSINESS Eisai Announces Organizational Reforms; “We Won’t Allow Generics to Overwhelm AD Market”: President Naito
April 12, 2013
-
BUSINESS Shire Enters Japan Full Force, Six Products to Be Launched in Five Years
April 11, 2013
-
BUSINESS Amgen Plans New Product Debuts in Japan by 2016, Pins Hopes on Hyperlipidemia Drug
April 10, 2013
-
BUSINESS Rubella Epidemic Triggers Vaccine Shipment Adjustments at Drug Makers
April 9, 2013
-
REGULATORY MHLW Unveils Generic Roadmap, Aims for 60%-Share by FY2017
April 8, 2013
-
BUSINESS Takeda to Successively File 2 New Diabetes Drugs in Japan
April 5, 2013
-
BUSINESS Protected Drugs Represent More than 50% of Bayer Yakuhin Sales in 2012, Over 60% Eyed by 2014: Pres. Brunn
April 4, 2013
-
BUSINESS Presidents of Pharmaceutical Companies Stress Globalization, Compliance in Welcoming Ceremonies for New Employees
April 4, 2013
-
BUSINESS Janssen Poised to Keep Up Double-Digit Growth, Focus on 5 Therapeutic Areas: Japan Pres. Goodwin
April 3, 2013
-
BUSINESS AZ Takes Over Rights to Byetta and Bydureon; Bydureon Expected to Be Launched in May
April 2, 2013
-
BUSINESS DSP Signs Agreement with Edison Pharmaceuticals of US for Mitochondrial Disease Treatments
April 2, 2013
-
ORGANIZATION Pharma Officials Puzzled at Fuzzy Communications Provision in JPMA Code of Practice
April 1, 2013
-
REGULATORY MOF Budget Examiner Hirotsugu Shinkawa Hopes to See New Generic Target Set at Highest Share Achievable at Fastest Pace
March 29, 2013
-
REGULATORY MHLW’s Generic Roadmap Compilation in Homestretch
March 29, 2013
-
BUSINESS Otsuka, Lundbeck to Jointly Develop, Market Alzheimer’s Disease Drug
March 28, 2013
-
BUSINESS ASKA Targets Sales of 50 Billion yen in FY2015, Up 20% vs. FY2012 Outlook: 3-Year Plan
March 27, 2013
-
BUSINESS New Settai Rules Halfway to Establishment; Some in Industry Want Further Rules as Well
March 26, 2013
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…